Skip to main content
    N

    Nuvation Bio Inc (NUVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $3.91
    +0.07 (+1.82%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Nuvation Bio Inc (NUVB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Nuvation Bio (NUVB) has a market cap of $1.41B and an enterprise value of $1.54B. Revenue grew 968.77% over the last 12 months from the 12 months before. It kept -67.38% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 9.35% above the market cap, as debt exceeds cash.

    Market Cap$1.41B
    Enterprise Value$1.54B
    Latest price (Nov 17, 2026)$3.91

    Key Dates

    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.89% in the quarter ended Sep 30, 2026 and grew 13.41% a year over 2 years.

    Shares Outstanding351.86M
    Shares Change (YoY)+2.77%
    Shares Change (QoQ)+0.89%
    Share Count Growth (2Y CAGR)+13.41%

    Valuation Ratios

    Sales and book value multiples are 6.8x and 6.0x.

    P/S Ratio6.8x
    Forward P/S6.9x
    P/B Ratio6.0x
    P/TBV Ratio6.6x

    Price Statistics

    The stock is down 19.55% over 52 weeks and trades 22.11% below its 50-day average.

    Beta (1Y)1.74
    52-Week Change-19.55%
    1-Month Change-12.72%
    3-Month Change-46.14%
    6-Month Change-7.78%
    5-Year Change-48.09%
    Total Return (1Y)-19.55%
    Total Return (3Y CAGR)+41.49%
    Total Return (5Y CAGR)-16.17%
    Return vs SPY (1Y)-30.10%
    Max Drawdown (1Y)-59.75%
    Max Drawdown (3Y)-59.75%
    Sharpe Ratio (1Y)-0.26
    Correlation with SPY (1Y)0.30
    50-Day Average$5.02
    200-Day Average$5.31
    52-Week Range$3.82 to $9.75
    RSI (14 Days)32.4
    Average Volume (20 Days)5.21M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.45x current liabilities, and total debt is 1.25x shareholder equity.

    Current Ratio7.45x
    Quick Ratio7.30x
    Debt / Equity1.25x
    Interest Coverage-3.40x

    Returns and Efficiency

    Return on invested capital is -18.68% over the last 12 months, against a 5-year average of -73.36%.

    Return on Equity (ROE)-59.63%
    Return on Assets (ROA)-17.46%
    Return on Invested Capital (ROIC)-18.68%
    Return on Capital Employed (ROCE)-17.85%
    ROE (5Y Average)-45.89%
    ROA (5Y Average)-35.67%
    ROIC (5Y Average)-73.36%
    Asset Turnover0.29x
    Receivables Turnover6.27x
    Cash Conversion Cycle-254 days

    Scores

    NUVB has an Altman Z-Score of 0.04, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score0.04
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $201.73M over the last 12 months.

    Revenue$201.73M
    Revenue Growth (YoY)+968.77%
    Gross Profit$209.75M
    Operating Income-$123.40M
    Pretax Income-$135.93M
    Net Income-$135.93M
    EBITDA-$121.54M
    EBIT-$121.36M
    Reported EPS (TTM)-$0.37

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 29.29% of the $778.39M in total assets.

    Cash and Equivalents$153.77M
    Total Debt$285.43M
    Net Debt$131.66M
    Net Debt Per Share$0.37
    Working Capital$636.10M
    Shareholder Equity$227.97M
    Book Value Per Share$0.65
    Tangible Book Value$208.18M
    Tangible Book Per Share$0.59
    Total Assets$778.39M
    Total Liabilities$550.42M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.98M of capital spending, operating cash flow left -$108.17M of free cash flow.

    Operating Cash Flow-$106.19M
    Capital Expenditures$1.98M
    Free Cash Flow-$108.17M
    FCF Per Share-$0.31
    Depreciation and Amortization$4.55M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -61.17%.

    Gross Margin103.98%
    Operating Margin-61.17%
    Pretax Margin-67.38%
    Net Margin-67.38%
    EBITDA Margin-60.25%
    EBIT Margin-60.16%
    FCF Margin-53.62%

    Growth

    Book Value Per Share Growth (2Y CAGR)-43.33%
    Tangible Book Per Share Growth (2Y CAGR)-44.38%

    Revenue and profit by year

    Dividends and Yields

    NUVB does not pay a dividend. Its free cash flow yield is -7.86%.

    FCF Yield-7.86%
    Buyback Yield-0.06%
    Shareholder Yield-0.06%

    Peer Position

    Against 8 similar companies, NUVB has the 4th highest P/S.

    P/S Ratio6.8x vs 4.2x median
    ROIC-18.68% vs -66.62% median
    Revenue Growth (Trailing 4 Quarters, YoY)+968.77% vs -1.91% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 99.71% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+99.71%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About NUVB

    What is NUVB's market cap?

    Nuvation Bio has a market cap of $1.41B. Its enterprise value, which adds debt and subtracts cash, is $1.54B.

    How many shares of NUVB are outstanding?

    Nuvation Bio has 351.86M shares outstanding. The count is up 2.77% from a year earlier.

    Does NUVB pay a dividend?

    No. Nuvation Bio does not pay a dividend.

    How much debt does NUVB have?

    Nuvation Bio has $285.43M of total debt and $153.77M of cash and equivalents, a net debt position of $131.66M.